Deramiocel CRL Rejects Modest PUL Wins Despite Two Randomized Trial Hits
Regulatory Approvals

Deramiocel CRL Rejects Modest PUL Wins Despite Two Randomized Trial Hits

Published : 22 Nov 2026

At a Glance
IndicationDuchenne muscular dystrophy
DrugDeramiocel
Mechanism of ActionCell therapy (cardiosphere-derived cells)
CompanyCapricor Therapeutics
Trial PhasePhase 3
Trial AcronymHOPE-2, HOPE-3
CategoryRegulatory Milestone
Sub CategoryComplete Response Letter (CRL)
Therapeutic AreaRare Diseases & Genetics
Regulatory EventComplete Response Letter (CRL)
Regulatory AgencyU.S. Food and Drug Administration (FDA)
Application TypeBiologics License Application (BLA)
Regulatory DesignationsOrphan Drug, RMAT, Rare Pediatric Disease (U.S.), Orphan Drug, ATMP (Europe)
Cash Position$198.5 million
Cash Position DateSeptember 30, 2026
Cash RunwayAt least the next 12 months
Conference Call DateMonday, November 23
Conference Call Time8:30 a.m. ET
Patient Population Size (DMD)Approximately 15,000 individuals in the United States

FDA Issues Complete Response Letter for Capricor's Deramiocel BLA

Capricor Therapeutics announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its resubmitted Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The FDA cited insufficient data to establish substantial evidence of effectiveness and other clinical deficiencies. Capricor's CEO, Linda Marbán, Ph.D., expressed disappointment but affirmed the rigor of their clinical program, noting that two prior trials, HOPE-2 and HOPE-3, met their primary endpoints. The company is reviewing the CRL to determine next steps. Capricor reported approximately $198.5 million in cash as of September 30, 2026, which is expected to fund operations for at least the next 12 months.

  • The U.S. FDA issued a Complete Response Letter for Capricor's Deramiocel BLA, explicitly stating that the submitted data did not provide sufficient evidence to establish effectiveness. The letter also highlighted additional unspecified clinical deficiencies, indicating that the application, in its current form, cannot be approved.
  • Capricor Therapeutics expressed strong disagreement with the FDA's assessment, emphasizing the robustness of its clinical program. The company highlighted that Deramiocel was evaluated in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which successfully met their primary endpoints, supporting the therapy's potential.
  • Despite the regulatory setback, Capricor reported a solid financial position with approximately $198.5 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026. This capital is projected to fund planned operations for at least the next 12 months, with ongoing efforts to optimize operating costs for an extended cash runway.

The Persistent Challenges in Duchenne Muscular Dystrophy Treatment

Current treatment approaches for Duchenne muscular dystrophy improve muscle strength and function but face persistent trade-offs between short-term benefit and long-term harm. Corticosteroids remain standard of care, while gene therapy and exon-skipping therapies introduce targeted options constrained by safety, durability and eligibility.

  • Corticosteroid morbidities limit chronic use: Chronic corticosteroid treatment causes significant morbidities, including excessive weight gain, behavioural abnormalities, cushingoid appearance, and excessive hair growth, with stunting of growth seen with corticosteroids, and bone health, growth parameters, and cataracts worse with deflazacort in comparative assessments.

  • Uncertainty on long-term benefit and optimal regimen: Questions remain over ability to prolong walking, when to start treatment, longer-term balance of benefits versus harms, and choice of corticosteroid or regimen, with no evidence other than from non-randomised trials to establish effect on prolongation of walking and inability to evaluate long-term benefits and hazards from published RCTs.

  • Gene therapy durability and immune-mediated safety challenges: Delandistrogene moxeparvovec has demonstrated transgene expression and potential functional improvement in early phase trials, although long-term efficacy, durability, and safety remain unconfirmed, with immune-mediated toxicities including myositis, myocarditis, and liver injury, plus thrombotic microangiopathy cases and patient deaths due to acute liver failure leading to program discontinuation for fordadistrogene movaparvovec.

  • Vector, immunogenicity and system constraints: Key issues include immunogenicity against AAV capsids and transgene products, durability of expression, and need for re-dosing or combinatorial strategies, with need to overcome vector size limitations by using dual/triple AAV systems or non-viral platforms, and difficult economic and logistical challenges for healthcare systems.

  • Exon-skipping therapies face limited eligibility and evidentiary gaps: The four FDA-approved ASO therapies — eteplirsen, golodirsen, viltolarsen, and casimersen — highlight critical challenges including complexities in clinical trial design, discrepancies between preclinical efficacy and clinical outcomes, real-world burdens, and limited patient eligibility, with FDA accelerated approval based on limited clinical data remaining a subject of ongoing debate and confirmatory trials to verify clinical efficacy actively underway.

Deramiocel's Clinical Program: HOPE-2 and HOPE-3 Data

Key Duchenne muscular dystrophy trials span AAV-based micro-dystrophin gene therapy, exon-skipping oligomers, cardiac prophylaxis, corticosteroid comparisons and repurposed tamoxifen. Designs range from small open-label dose-escalation studies to multicenter randomized double-blind placebo-controlled phase 3 trials, with endpoints centered on North Star Ambulatory Assessment, timed function tests, 6-minute walk distance, cardiac function and dystrophin expression.

Trial Design and Population Intervention Endpoints
EMBARK Phase 3, NCT05096221 Phase 3, two-part, crossover, randomized, placebo-controlled trial in ambulatory male patients with DMD aged 4 to < 8 years; N = 125, randomized to delandistrogene moxeparvovec n = 63 or placebo n = 62, stratified by age group and North Star Ambulatory Assessment score Single intravenous dose delandistrogene moxeparvovec 1.33 × 10 vector genomes/kg, recombinant adeno-associated virus rhesus isolate serotype 74 vector-based gene therapy Primary: change from baseline in North Star Ambulatory Assessment total score at 52 weeks; Secondary: micro-dystrophin expression at week 12, Time to Rise, 10-meter Walk/Run, stride velocity 95th centile, 100-meter Walk/Run, time to ascend 4 steps, PROMIS Mobility and Upper Extremity, number of NSAA skills gained/improved, adverse events
rAAVrh74.MHCK7.micro-dystrophin Phase 1/2a, NCT03375164 Open-label, phase 1/2a nonrandomized controlled trial at Nationwide Children's Hospital in Columbus, Ohio; 4 ambulatory male children with DMD without preexisting AAVrh74 antibodies and stable corticosteroid dose ≥12 weeks, mean age 4.8 years Single dose 2.0 × 1014 vg/kg rAAVrh74.MHCK7.micro-dystrophin infused through peripheral limb vein; daily prednisolone 1 mg/kg started 1 day before delivery with 30-day taper Primary: safety and tolerability; Secondary: micro-dystrophin expression by Western blot and immunohistochemistry; Exploratory: North Star Ambulatory Assessment scores and serum creatine kinase
Enalapril and metoprolol cardiac trial, DRKS-number 00000115 Sixteen weeks single-arm open run-in therapy followed by two-arm 1:1 randomized double-blind placebo-controlled treatment in multicenter setting; 38 patients centrally randomized, 21 continuing medication and 17 receiving placebo; DMD boys aged 10-14 years with left ventricular fractional shortening ≥ 30% Combined ACE-inhibitor enalapril and β-blocker metoprolol versus placebo Primary: time from randomization to first occurrence of LV-FS < 28%; Secondary: changes of LV-FS from baseline, blood pressure, heart rate and autonomic function in ECG and Holter-ECG, cardiac biomarkers and neurohumeral serum parameters, quality of life, adverse events
Tamoxifen in DMD (TAMDMD), NCT03354039 Multicenter, randomized, double-blind, placebo-controlled phase III trial with open-label extension; at least 71 ambulant and up to 20 nonambulant patients with DMD planned at multiple European sites Tamoxifen 20 mg or placebo daily over 48 weeks, followed by tamoxifen for further 48 weeks in extension Primary: change of D1 domain of motor function measure in ambulant patients or D2 domain in nonambulant patients; Secondary: change in timed function tests, quantitative muscle testing, quantitative magnetic resonance imaging of thigh muscles, biomarkers of tamoxifen metabolism and muscle dystrophy
AVI-4658 exon 51 skipping Phase 2, NCT00844597 Open-label, phase 2, dose-escalation study in ambulant patients aged 5-15 years with amenable deletions in DMD; 19 patients across 0.5, 1.0, 2.0, 4.0, 10.0, and 20.0 mg/kg cohorts with muscle biopsy before treatment and after 12 weekly intravenous infusions Intravenously administered AVI-4658 phosphorodiamidate morpholino oligomer Primary: safety and tolerability; Secondary: pharmacokinetic properties and exon 51 skipping and dystrophin restoration by RT-PCR, immunohistochemistry, and immunoblotting
ACT DMD post hoc corticosteroid analysis, NCT01826487 48-week trial of ataluren for nonsense mutation DMD; post hoc comparison in placebo arm receiving stable corticosteroids ≥6 months, deflazacort n = 53 versus prednisone/prednisolone n = 61 Deflazacort versus prednisone/prednisolone Change from baseline to week 48 in 6-minute walk distance, timed function tests including 4-stair climb, estimated age at loss of ambulation extrapolated from 6MWD

The Evolving Duchenne Muscular Dystrophy Treatment Landscape

Vamorolone, described as a dissociative corticosteroid (CS) approved by the US Food and Drug Administration in 2023 for treating Duchenne muscular dystrophy (DMD), has been evaluated as an alternative to classic corticosteroids. In a randomized, double-blind, placebo- and prednisone-controlled 24-week clinical trial conducted from June 29, 2018, to February 24, 2021 in boys 4 to younger than 7 years of age with genetically confirmed DMD not previously treated with corticosteroids, 121 were randomly assigned to treatment groups, and 114 completed the 24-week treatment period. The trial met the primary end point for change from baseline to week 24 time to stand velocity for vamorolone, 6 mg/kg per day with least-squares mean [SE] velocity, 0.05 [0.01] m/s vs placebo -0.01 [0.01] m/s; 95% CI, 0.02-0.10; P = .002. Height percentile declined in prednisone-treated participants with change from baseline [SD] of prednisone, -1.88 [8.81] percentile vs vamorolone, 6 mg/kg per day, +3.86 [6.16] percentile; P = .02, while bone turnover markers declined with prednisone but not with vamorolone. Over 48 weeks, vamorolone at a dose of 6 mg/kg/d showed maintenance of improvement for all motor outcomes to week 48 with time to stand from supine [TTSTAND] velocity, week 24 least squares mean [LSM] [SE] 0.052 [0.0130] rises/s vs week 48 LSM [SE] 0.0446 [0.0138]. Phase II, open-label, multiple-dose study VBP15-006 evaluated 2 or 6 mg/kg/d oral vamorolone for 12 weeks in CS-naive boys aged 2-<4 years in Canada and in 34 participants aged 7- to <18 years either corticosteroid-untreated or switching from prior CS treatment, followed by an expanded access protocol. In 2-<4-year-old boys, TEAEs were mostly mild, with no deaths, serious TEAEs, or TEAEs leading to drug discontinuation during VBP15-006, with stable growth trajectories and dose-dependent improvements in motor function measured by Bayley-III gross motor scaled score. In 7- to <18-year-old boys, all 34 participants completed VBP15-006 and entered EAP Canada, with CS-untreated participants maintaining stable linear growth while CS-treated participants exhibited catch-up growth, and 2 individuals who switched from deflazacort to vamorolone 2 mg/kg/day had generalized weakness consistent with adrenal insufficiency.

Systemic delivery of recombinant adeno-associated virus serotype rh74 vector-based gene therapy addressing the absence of functional dystrophin has advanced through early-phase to phase 3 testing. In an open-label, phase 1/2a nonrandomized controlled trial at Nationwide Children's Hospital beginning November 2, 2017, 4 patients with mean [SD] age at enrollment, 4.8 [1.0] years received a single dose of 2.0 × 1014 vg/kg rAAVrh74.MHCK7.micro-dystrophin infused through a peripheral limb vein with daily prednisolone, 1 mg/kg, started 1 day before gene delivery. All adverse events (n = 53) were considered mild (33 [62%]) or moderate (20 [38%]), and no serious adverse events occurred, with vomiting in 9 of 18 treatment-related events [50%] as most common. At 12 weeks, immunohistochemistry revealed robust transgene expression with a mean of 81.2% of muscle fibers expressing micro-dystrophin with a mean intensity of 96% at the sarcolemma, and Western blot showed a mean expression of 74.3% without fat or fibrosis adjustment and 95.8% with adjustment. EMBARK is a phase 3, two-part, crossover, randomized, placebo-controlled trial assessing single intravenous dose 1.33 × 10 vector genomes/kg delandistrogene moxeparvovec in ambulatory male patients aged 4 to < 8 years; N = 125. The primary endpoint of change from baseline in North Star Ambulatory Assessment [NSAA] total score at 52 weeks compared with placebo did not meet statistical significance, but at 2 years patients showed statistically significant benefit versus a matched propensity score-weighted external control in NSAA, Time to Rise, and 10-m Walk/Run with no new safety signals between week 52 and week 104. In ENDEAVOR cohort 1 with N = 20 ambulatory males aged ≥4 to <8 years, mean (SD) change from baseline to week 12 in western blot was 54.2% (42.6); p < 0.0001, and at 1 year mean (SD) change from baseline in NSAA was +4.0 (3.5) with least squares mean (standard error) difference versus external control of +3.2 (0.6) points; p < 0.0001.

Exon-skipping phosphorodiamidate morpholino oligomers for specific DMD mutations have reported long-term safety and biologic activity. In a multicenter, phase 1/2 trial enrolling 12 participants aged 7-21 years with limited ambulation or nonambulatory status amenable to exon 45 skipping, participants were randomized 2:1 to weekly casimersen infusions at escalating doses of 4, 10, 20, and 30 mg/kg or placebo during 12-week double-blind dose titration then open-label extension for up to 132 weeks. Participants received casimersen for a mean 139.6 weeks, treatment-emergent adverse events occurred in all casimersen- and placebo-treated participants and were mostly mild (over 91.4%) and unrelated to casimersen or its dose, with no deaths, dose reductions, or casimersen-related serious AEs, and plasma exposure was dose proportional with no suggestion of plasma accumulation. In a Phase 1/2, 2-part, multicenter trial of golodirsen 30 mg/kg in ambulatory patients with exon 53 skip-amenable DMD, golodirsen increased dystrophin protein (16.0-fold; P < 0.001) and exon skipping (28.9-fold; P < 0.001). At 3 years, 6MWT change from baseline was -99.0 m for golodirsen-treated patients versus -181.4 m for external controls (P = 0.067), and loss of ambulation occurred in 9% versus 26% (P = 0.21), with FVC%p declining 8.4% over 3 years.

Frequently Asked Questions

How does Deramiocel address the underlying pathology of Duchenne muscular dystrophy?
Deramiocel is an investigational gene therapy designed to deliver a functional copy of the dystrophin gene to muscle cells. This approach aims to restore dystrophin protein production, which is deficient in Duchenne muscular dystrophy, thereby potentially mitigating muscle degeneration. Its mechanism targets the genetic root cause of the disease, offering a novel therapeutic strategy.
What are the current therapeutic challenges in Duchenne muscular dystrophy that Deramiocel aims to address?
Current Duchenne muscular dystrophy treatments primarily focus on symptom management and slowing disease progression, often involving corticosteroids and exon-skipping therapies for specific mutations. Significant unmet needs remain, particularly for therapies that can broadly restore dystrophin function or halt muscle degeneration across all genetic subtypes. Deramiocel seeks to address these gaps by providing a systemic gene therapy approach.
What are the key considerations for regulatory bodies evaluating novel gene therapies for Duchenne muscular dystrophy?
Regulatory bodies evaluating novel gene therapies for Duchenne muscular dystrophy prioritize evidence of safety, efficacy, and durability of effect. Key considerations include the potential for long-term dystrophin expression, functional improvements, and the management of immune responses to the viral vector. The severity and progressive nature of DMD often lead to accelerated review pathways for promising therapies.
How might the introduction of a gene therapy like Deramiocel impact the long-term management paradigm for Duchenne muscular dystrophy?
The introduction of a gene therapy like Deramiocel could fundamentally shift the long-term management paradigm for Duchenne muscular dystrophy from palliative care to disease modification. It offers the potential for a one-time treatment that could significantly alter the natural history of the disease, reducing the burden of progressive muscle weakness. This could lead to earlier intervention strategies and a re-evaluation of standard care protocols.

References

  1. [1] Shieh PB, Elfring G et al.. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. Journal of comparative effectiveness research. 2021 Dec. 34693725
  2. [2] Goemans N, Vanden Hauwe M et al.. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. PloS one. 2016. 27737016
  3. [3] Im YJ, Choe Y et al.. Quantitative Muscle Ultrasound: A Non-Invasive Biomarker for Monitoring Duchenne Muscular Dystrophy. Muscle & nerve. 2025 Oct. 40671379
  4. [4] Zaidman CM, Goedeker NL et al.. Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy. Journal of neuromuscular diseases. 2024. 38607761
  5. [5] Hu M, Xu T et al.. [Characteristics and changes of cardiac injury with age in children of Duchenne muscular dystrophy: a prospective cohort study]. Zhonghua er ke za zhi = Chinese journal of pediatrics. 2024 Mar 2. 38378283
  6. [6] Mazzone E, Martinelli D et al.. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscular disorders : NMD. 2010 Nov. 20634072
  7. [7] Van Dorn CS, Puchalski MD et al.. DMD mutation and LTBP4 haplotype do not predict onset of left ventricular dysfunction in Duchenne muscular dystrophy. Cardiology in the young. 2018 Jul. 29766838
  8. [8] Flotats-Bastardas M, Ebrahimi-Fakhari D et al.. [Non-ambulatory patients with Duchenne muscular dystrophy : Recommendations for monitoring disease progression and course of treatment]. Der Nervenarzt. 2019 Aug. 31270551
  9. [9] Hakim CH, Clément N et al.. Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease. Molecular therapy. Methods & clinical development. 2020 Sep 11. 32775499
  10. [10] Moriyama H, Moriyama S et al.. FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook. RNA biology. 2026 Dec. 42324661
  11. [11] McCormack NM, Nguyen NY et al.. Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice. iScience. 2023 Jul 21. 37534133
  12. [12] Nagy S, Hafner P et al.. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Trials. 2019 Nov 21. 31752977
  13. [13] Dittrich S, Graf E et al.. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. Orphanet journal of rare diseases. 2019 May 10. 31077250
  14. [14] Wang S, Kidwell KM et al.. Dynamic enrichment of Bayesian small-sample, sequential, multiple assignment randomized trial design using natural history data: a case study from Duchenne muscular dystrophy. Biometrics. 2023 Dec. 37323055
  15. [15] McDonald CM, Signorovitch J et al.. Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials. PloS one. 2024. 38829874
  16. [16] Mayhew AG, Moat D et al.. Functional outcome measures in young, steroid-naïve boys with Duchenne muscular dystrophy. Neuromuscular disorders : NMD. 2022 Jun. 35618576
  17. [17] Shimizu-Motohashi Y. Gene therapy for Duchenne muscular dystrophy. Brain & development. 2025 Oct. 40848523
  18. [18] Bilchick KC, Salerno M et al.. Prevalence and distribution of regional scar in dysfunctional myocardial segments in Duchenne muscular dystrophy. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance. 2011 Mar 11. 21396105

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts